The Anthrax Vaccine


Book Description

The vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA. The Anthrax Vaccine: Is It Safe? Does It Work? reports the study's conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.







Vaccine A


Book Description

In this provocative look at the US military from the Persian Gulf War through the 2003 invasion of Iraq, investigative journalist Gary Matsumoto contends that an anthrax vaccine dispensed by the Department of Defense was the cause of Gulf War Syndrome and the origins of a massive cover-up. Matsumoto calls it the worst friendly-fire incident in military history. A skillfully-woven narrative that serves as a warning about this man-made epidemic, Vaccine A is a much needed account of just what went wrong, and why.




The Anthrax Immunization Program


Book Description




Department of Defense Anthrax Vaccine Immunization Program


Book Description

Witnesses: Rear Admiral Lowell E. Jacoby, U.S. Navy, Director, Intelligence Directorate, Office of the Joint Chiefs of Staff; Rudy de Leon, Deputy Secretary of Defense; David R. Oliver, Principal Deputy Under Secretary of Defense for Acquisition & Technology; Lt. Gen. Ronald R. Blanck, U.S. Army, Surgeon General of the Army; Major General Randall L. West, U.S. Marine Corps, Special Advisor to the Under Secretary of Defense for Personnel & Readiness; Carol R. Schuster, Associate Director for National Security Preparedness Issues, National Security & International Affairs Div., U.S. General Accounting Office.










The Anthrax Vaccine


Book Description

The vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA. The Anthrax Vaccine: Is It Safe? Does It Work? reports the study's conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.




Department of Defense Anthrax Vaccine Immunization Program (AVIP)


Book Description

Witnesses: Rudy de Leon, Dep. Sec. of Def.; Tommy Franks, Jr., U.S. Army, Commander in Chief, U.S. Central Command; Randall West, U.S. Marine Corps, Sr. Advisor to the Dep. Sec. of Def. for Chem. & Biol. Protection; J. Jarrett Clinton, Public Health Serv., 1st Assist. to the Assist. Sec. of Def. for Health Affairs; Anna Johnson-Winegar, Dep. Assist. Sec. of Def. for Chem. & Biol. Def.; Gaston Randolph, Jr., U.S. Army, Dir., AVIP; Fuad El-Hibri, CEO, Bioport Corp., accomp. by Robert Myers, Chief Scientific Officer, & Robert Kramer, CFO, Bioport Corp.; April Stephenson, Chief, Policy Programs Div., Defense Contract Audit Agency; & Kathryn Zoon, Dir., Center for Biologics Evaluation & Res., FDA